Navigation Links
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT

RARITAN, N.J., June 28 /PRNewswire/ -- Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the signing of a five-year collaboration agreement with the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.  Called TRANSCEND, the collaboration agreement will foster oncology research and technology development in the areas of cancer diagnostics, cancer biology pre-malignancies, genetic models of disease, and profiles of the tumor microenvironment.

"The TRANSCEND program embodies our external innovation approach to research," said William N. Hait, M.D., Ph.D., Global Therapeutic Area Head, Oncology, for Johnson & Johnson Pharmaceutical Research & Development, L.L.C., an affiliate of Ortho-McNeil Janssen.  "By collaborating with leading academic institutions and colleagues at the interface of engineering and biology, we're able to bring together the best scientific minds in industry and academia to meet unmet medical needs in patients with cancer."

A Joint Scientific Steering Committee composed of MIT faculty members and Ortho-McNeil Janssen employees will jointly review and select proposals from MIT researchers for funding.  Projects will involve interdisciplinary faculty, students and staff to address oncology solutions.  In addition, there is the potential for visiting scientists from Ortho-McNeil Janssen to participate in projects within the investigators' laboratories at the Koch Institute.

"The visiting scientist aspect of the program is designed to promote interactive exchange between our organizations at the bench," said Hait.  "We believe both organizations will benefit from our scientists' experience of learning, interacting and innovating together."  

About Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) provides medicines for an array of health concerns.  The company strives to provide innovative, high quality, safe and effective treatments and continually seeks new opportunities to offer solutions for unmet health care needs. Ortho-McNeil-Janssen Pharmaceuticals, Inc. is headquartered in Raritan, New Jersey.

SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
2. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
5. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
(Date:11/24/2015)... BERN, Switzerland , November 24, 2015 ... for Biomedical Engineering Research of the University of ... Endocrinology, Diabetes and Clinical Nutrition of the Bern University ... an exclusive collaboration to develop a novel generation artificial ... personalised delivery of insulin for diabetic patients with the ...
(Date:11/24/2015)... 2015 st  Scientific Assembly and Annual Meeting ... (RSNA) taking place in Chicago on Nov-29 ... --> st  Scientific Assembly and Annual Meeting of the ... place in Chicago on Nov-29 th ... Molecular Dynamics will present its revolutionary whole body CZT digital ...
Breaking Medicine Technology:
(Date:11/24/2015)... , ... November 24, 2015 , ... Aided by seed ... announced an innovative study designed to yield insights into how to detect and treat ... biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that is ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Rodney E. Willey , has answered a ... Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea through ... a Koala Center for Sleep Disorders in the US, one of four in the Illinois ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Autism Speaks, ... the global movement driven by social media and the generosity of people around the ... encourage their social media networks to give – and share the personal stories behind ...
(Date:11/24/2015)... Tennessee (PRWEB) , ... November 24, 2015 , ... ... Pharmacy Quality Trend Report . Throughout the past year there have been multiple breakthroughs ... mature state. During this transition, PharmMD has enabled their customers and partners to stay ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... “I am so thrilled, as a newbie ... after learning she had won a $7,500 School Lounge Makeover® from California Casualty . ... most of the staff has a much longer tenure. , “This is such an amazing ...
Breaking Medicine News(10 mins):